Rob Scott, MD 

Board Member

Dr Scott joined the Arcutis Board of Directors in October 2026. He is a physician, pharmaceutical industry leader, and drug development pioneer with more than 40 years of experience advancing innovative medicines from discovery through regulatory approval. Most recently, he served as chief medical officer at AbbVie, where he oversaw a portfolio of approximately 40 new molecular entities and a global organization of 4,000 team members. During his tenure, AbbVie secured more than 14 major regulatory approvals, including Venclexta^®, Orilissa^®, Skyrizi^®, and Rinvoq^®.

Prior to AbbVie, Dr Scott served as vice president of global development at Amgen, where he led the development and approval of Repatha^®. Earlier in his career, he held leadership roles at Pfizer, where he contributed to the development of Lipitor^® and Norvasc^® and invented and developed Caduet^®, the first commercially available polypill. He also led the first large cardiovascular outcomes study conducted entirely by a biotechnology company while at AtheroGenics.

Dr Scott has served on numerous public and private company boards, as well as scientific and strategic advisory boards. He was a member of the FDA Cardiac and Renal Drug Advisory Committee from 2012 to 2016. Dr Scott earned his medical degree from the University of Cape Town.